On 27 June 2018 the Canadian Agency for Drugs and Technologies in Health (CADTH) published the Procedure and Submission Guidelines for the CADTH Common Drug Review, which consolidate two previously separate guidelines and include a number of revisions to the submission requirements.
These changes are summarised in CDR Update – Issue 138 and will be enforced for all submissions and resubmissions received on or after 27 July 2018.
For further information on this topic please contact Abigail Smith at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email (email@example.com). The Smart & Biggar website can be accessed at www.smart-biggar.ca.
This article was first published by the International Law Office, a premium online legal update service for major companies and law firms worldwide. Register for a free subscription.